Healthcare News

The latest healthcare stories, summarized by AI

healthcare11.28 min read

Structured stress test reveals safety gaps in ChatGPT Health triage

2 days agoSource: Nature
View original source
UK prostate cancer patients denied life-preserving focal therapy
healthcare
14.43 min2 days ago

UK prostate cancer patients denied life-preserving focal therapy

Thousands of UK men with prostate cancer are reportedly being denied focal therapy, a non-invasive treatment that preserves quality of life by reducing side effects like erectile dysfunction and incontinence; despite three principal forms (HIFU, cryotherapy, NanoKnife) being available, the NHS offers access at only a few centres and doctors say patients aren’t routinely informed about this option, prompting calls for broader access amid supportive trial data and NICE approvals.

More Healthcare Stories

US Hospitals Dominate Global Top Brand Rankings
healthcare15 days ago

US Hospitals Dominate Global Top Brand Rankings

The United States leads the global map of hospital brands with 25 entries in the top 100, while the United Kingdom anchors Europe with eight and Australia over‑indexes with five. North America accounts for 29 brands in the top 100; Johns Hopkins Medicine is #1 globally, and Oxford and Cambridge hospitals anchor the UK’s strong European showing. The analysis includes 14 MENA hospitals in the top 100, based on Brand Finance’s Global Top 250 Hospitals 2026, illustrating how brand strength shapes patient choice, clinician recruitment, and prestige across nations.

FDA nixes Regenxbio Hunter syndrome gene therapy over trial design concerns
healthcare16 days ago

FDA nixes Regenxbio Hunter syndrome gene therapy over trial design concerns

The FDA rejected Regenxbio’s RGX-121 for Hunter syndrome, citing unresolved issues in the trial design (defining the patient population), use of a natural history control, and a biomarker surrogate endpoint, with a PDUFA date already pushed from 2025. Regenxbio plans to resubmit with longer-term data. The decision follows a broader context of safety concerns linked to Regenxbio’s RGX-111 and its brain-tumor event, but the FDA noted those issues were not cited as reasons for RGX-121’s rejection. Industry experts emphasize ongoing questions around biomarker-based approvals and vector-related safety, underscoring the urgent need for effective therapies in these ultra-rare MPS diseases.

Vermont Tops 2026 ACA Premiums as U.S. Health-Costs Rise
healthcare16 days ago

Vermont Tops 2026 ACA Premiums as U.S. Health-Costs Rise

A Voronoi visualization maps 2026 average monthly ACA Silver-plan premiums by state, with Vermont highest at $1,224; the national average is $752 (up 21% from 2025) as subsidies expire and insurers raise costs. Vermont also spends about 19.6% of income on healthcare, more than triple the U.S. average of 7.9%. Maryland has the lowest premiums at $480, while other states range up to about $1,100 (Wyoming $1,119; West Virginia $1,093). Alaska is the only state with a premium decline year over year; substantial increases occur in Nebraska (29%), Illinois (30%), Florida (33%), Connecticut (21%), and Louisiana (26%).

TrumpRx launches price-cut drug portal listing 43 meds for cash buyers
healthcare19 days ago

TrumpRx launches price-cut drug portal listing 43 meds for cash buyers

Trump announced TrumpRx, a new online portal that lists discounted prices for 43 commonly used drugs and directs consumers to manufacturers’ sites to complete purchases. The site does not sell meds or accept insurance; discounts apply only to cash-paying patients, with no impact on insurance deductibles. The White House says the portal offers immediate relief and plans to expand with more drugmakers, including notable discounts such as Wegovy as low as $149/month. It’s intended as a price-checking tool rather than a storefront.

Most TrumpRx-listed drugs have cheaper generics, study finds
healthcare19 days ago

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

MHRA warns Ozempic/Wegovy could cause rare eye condition
healthcare19 days ago

MHRA warns Ozempic/Wegovy could cause rare eye condition

Britain's MHRA has warned that the diabetes/weight‑loss injections Ozempic (semaglutide) and Wegovy may cause a rare optic nerve condition (NAION) that can lead to sudden vision loss in one eye. The regulator has received three reports, but says the overall risk is very small; with about two million UK users, patients and clinicians are advised to be alert to symptoms and seek urgent eye care if vision changes occur. The warning also notes that pancreatitis is a known but infrequent side effect of GLP-1 weight‑loss drugs.

TrumpRx.gov aims to slash U.S. drug prices via MFN discounts
healthcare20 days ago

TrumpRx.gov aims to slash U.S. drug prices via MFN discounts

President Trump launched TrumpRx.gov to offer steep discounts on 40 high-cost medicines by tying U.S. prices to MFN prices paid in other developed nations. The rollout includes drugs from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with additional products to follow. Patients with prescriptions can access savings via printable or mobile coupons or through manufacturer channels integrated into TrumpRx.gov. Notable examples include large price cuts for diabetes, obesity, fertility, COPD, asthma, and insulin, such as Ozempic, Wegovy, Zepbound, Gonal-F, Cetrotide, Ovidrel, and insulin lispro. The move builds on prior executive orders and agreements aimed at lowering prices and reforming how American drug costs are set.